Table 2 Demographic characteristics of Non-Responders and Super-Responders to CGRP(-R) mAbs

n

26

29

Female, n (%)

22 (85%)

-

22 (76%)

-

Age in years at first

administration, mean ± SD

50.5 ± 10.8

-

49.0 ± 10.7

-

Years lived with migraine,

mean ± SD

31.5 ± 19.1

4

30.2 ± 13.1

9

First mAb: n (%)

Erenumab: 14 (54%)

Fremanezumab: 4 (15%)

Galcanezumab: 8 (31%)

Erenumab: 12 (41%)

Fremanezumab: 10 (35%)

Galcanezumab: 7 (24%)

-

Second mAb: n (%)

Erenumab: 12 (46%)

Fremanezumab: 2 (8%)

Galcanezumab: 12 (46%)

-

-